abstract OBJECTIVE: Patient registries can effectively collect data over a long period of time to provide a better understanding of the typical presentation of specific conditions. The autism spectrum disorders (ASDs) have experienced a marked increase in reported prevalence over the past 20 years for reasons that are not completely clear. The Autism Treatment Network (ATN) Registry was established to facilitate investigations into a variety of questions critical to expanding our understanding of ASDs. Here we describe the establishment of the registry, its components, some of its findings to date, and opportunities for further use of this data.
The effective diagnosis and treatment of health conditions evolve from initial descriptions of the condition and efforts to ameliorate the condition's symptom manifestations. Gathering consistent data on aspects of the condition helps provide a better understanding of the condition and its variations. Similarly, through observation of responses to treatments, health care providers can learn more about the condition itself as well as make modifications to the treatment regimen. This iterative process moves forward continuously. The result is an increasingly detailed understanding of the condition itself, and more comprehensive and effective management of the condition.
Patient registries can effectively collect data over a long period of time to provide a better understanding of the typical presentation of specific conditions. By collecting a standard battery of assessments at baseline and at specific time points afterward, a registry can provide insight into the natural course of the condition. This process is especially helpful for relatively uncommon conditions for which the experience of a single practitioner or site may be limited by small numbers of affected patients. For example, registries have successfully promoted the delivery of guideline-concordant primary care for diabetes and hypertension. [1] [2] [3] Less-common conditions such as leukemia and other childhood cancers have benefited from similar patient registries.
The autism spectrum disorders (ASDs) have experienced a marked increase in reported prevalence over the past 20 years for reasons that are not completely clear. What is clear is that a condition with an estimated prevalence of ∼4 in 10 000 in the 1980s to early 1990s 4 has surged to a reported prevalence of 1 in 68 5 in a short period of time. The rapid growth has given urgency to increasing our limited understanding of the disorder to provide the best evidence-based care to this population. The Autism Treatment Network (ATN) Registry was established to serve this purpose.
DESCRIPTION OF THE REGISTRY
The Autism Speaks ATN was established in 2005 through a partnership between the Northwest Autism Foundation and the MassGeneral Hospital for Children's Learning and Developmental Disabilities Evaluation and Rehabilitation Services (LADDERS) program, now known as the Lurie Center for Autism. 6 The sites focused on developing a consensusbased model of care that provided multidisciplinary care, including medical evaluations to individuals on the autism spectrum; created a patient registry; and improved the quality of life for the individuals and their families. Clinicians at these programs were focused on medical aspects of autism that they felt were not receiving adequate attention and study and addressed these topics in their research. The ATN has previously been described in more detail. 6 
PARTICIPANTS
The ATN registry is composed of retrospective and prospective data on patients with ASD collected from the 14 ATN sites across the United States and Canada (Table 1) 
METHODS
The center submits the inclusion/ exclusion form to the ATN via the Internet System for Assessing Autistic Children (ISAAC) electronic data-capture system. During this process, the system provides a unique ATN participant identification number. This number is used throughout participation to identify all assessments for this individual. Centers also generate a Global Unique Identifier by using a computer program approved by the National Institutes of Health. This Global Unique Identifier reviews personal information and assigns a unique identification code that cannot be traced back to the personal information. Use of this number ensures that subjects, particularly those participating in genetic databases, are not duplicated in analyses. Subjects who consent and enroll in the ATN registry have de-identified baseline and follow-up information collected and processed. All data collected are managed and audited by the MassGeneral Biostatistics team, which serves as the ATN's Data Coordinating Center.
Baseline measures including demographics, autism assessment, Interim visit data should be collected at a maximum of once every 3 months (no more than quarterly).
c Assessments completed from a trusted source outside the ATN site will be accepted in the ATN registry.
cognitive assessment data, behavioral data, sleep habits, quality of life, sensory data, and medications were described. Frequencies for categorical variables were tabulated, and descriptive statistics (number of observations, means and SDs) were generated for continuous variables.
Counts were provided for the number of children with longitudinal data available for each measure.
RESULTS
The 13 and complementary and alternative therapies, 14 to name a few.
DISCUSSION
The goal of the registry is to provide data to identify medical conditions and comorbidities and to track medical, behavioral, and quality-of-life outcomes in children and adolescents with ASD to improve care, help identify best practices, and build a platform for research. The registry encompasses phenotypic data on medical, developmental, and behavioral concerns as well as family history.
The enrollment of well-characterized subjects into the registry has provided clarity to several controversial issues surrounding the physical aspects of autism. For example, there have been conflicting reports regarding the prevalence of gastrointestinal conditions in individuals with autism, running the gamut from no increase to a marked increase. The ATN registry, through its data collection, has been able to describe a high rate of gastrointestinal concerns in the enrolled subjects and first reported on this in 2010. 15 Studies by other investigators since then have confirmed an increase in gastrointestinal symptoms, including a recent study of infant symptom data collected prospectively before the children received an autism diagnosis. 16 The confirmation of an increased rate of gastrointestinal problems, especially constipation, led to network clinicians developing a best-practice pathway for the management of constipation in ASD. 17 These studies have also attempted to better identify clinical phenotypes. Data collected through the ATN registry have allowed for the examination of relationships between reported medical conditions and behaviors. 18, 19 Findings from these studies have also led to qualityimprovement work to increase awareness of medical providers to evaluate comorbid medical conditions when behavioral concerns are raised.
Analyses of other medical conditions accompanying ASD such as epilepsy and sleep disorders have been conducted with the registry data and used to guide the development of clinical interventions. Registry data identifying sleep problems, especially insomnia, led to work on effective treatments for these problems. 20, 21 More important, registries may answer questions that a clinical trial could never address. Wellcontrolled clinical trials can address very specific treatment strategies. Patient registries can provide data regarding several treatment measures or modalities and outcome variables, providing data to conduct retrospective comparative effectiveness analyses.
Although cross-sectional data are valuable, there is a critical need to track children over time to better examine the trajectory of medical comorbidities in ASD and their impact on neurodevelopmental outcomes. A subset of children in the current registry have longitudinal data (medical follow-up visits in years 1, 2, and 3), but attrition limits the data available for analysis. For example, the available sample size decreased by >50% for each subsequent follow-up visit on the PedsQL and the parent-form sleep problem question from baseline to the third follow-up visit. The ATN has recently made a focused effort to reduce attrition and increase the longitudinal data in the registry to provide researchers with more opportunities to examine medical and clinical changes in children with ASD over time. In addition, the National Institute of Mental Health has funded 2 pilot studies to also collect biospecimens (whole blood, cell lines, and urine) on a subset of the registry. Supplementing the registry data by collecting additional therapy information and outcome measures would allow more comparative effectiveness research to be conducted with these data.
More than 6800 children with ASD have been enrolled in the Autism Speaks ATN registry, and the ATN Data are presented as means ± SDs or n (%) unless otherwise indicated. ABC, Aberrant Behavior Checklist; ADHD, attention-defi cit/hyperactivity disorder; CAM, ; CGI, Clinical Global Impression rating scale; CGS, ; SSRI, serotonin reuptake inhibitor. a CGI starts at fi rst follow-up because it is a measure of improvement: basline = fi rst follow-up, fi rst follow-up = second follow-up, second follow-up = third follow-up. b IQ uses scores from Stanford-Binet (Full Scale and Investigators are encouraged to use the query tool to probe hypotheses or identify existing data on subjects with select characteristics. The ATN registry has already had an impact on patient care and conduct of pilot studies and has the potential to continue to do so for some time.
